The objective is to compare the progression of Atrial Fib (AF) burden by continuous monitoring in patients with recently diagnosed paroxysmal AF treated by catheter ablation (PVI) versus anti-arrhythmic drug (AAD) therapy.
Randomized, multicenter clinical trial comparing medical therapy (Group I) with ablation therapy(Group II). Randomization will be determined by opening a sealed envelope. All patients will be implanted with an implantable loop recorder and followed every three months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
propafenone, flecainide, sotalol, dofetilide
Complete PVI
Valley Health System
Ridgewood, New Jersey, United States
State Research Institute of Circulation Pathology
Novosibirsk, Russia
Percentage of AF burden
The percentage of AF burden defined through continuous monitoring using an implnatage loop recorder (ILR)
Time frame: 4 months
All-death death
All-cause death, thromboembolic events, hospitalizations, procedural complications, drug adverse effects, and number of crossovers
Time frame: 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.